Race Oncology Ltd (ASX:RAC) CEO and managing director Damian Clarke-Bruce speaks with Proactive soon after launching a new corporate strategy focused on maximising bisantrenes anti-cancer and cardio-protective potential.
The companys lead clinical focus will be on investigating anti-cancer, plus cardio-protective and FTO (fat mass and obesity-associated protein) properties in metastatic breast cancer, using the peripherally administered bisantrene formulation, RC220 with a view to improving therapeutic outcomes and heart health for patients with cancer.
Clarke-Bruce said: Races revised development program has been designed in such a way that our new bisantrene formulation can fit straight into a global pharmaceutical partner's pipeline.
Through our rigorous clinical development plan, Race will investigate bisantrene RC220 in both metastatic breast cancer and continue our clinical experience in AML, while investigating and expanding our knowledge of its mechanism of action.
We have a clear regulatory pathway and a program that is supported by international key opinion leaders, for a drug candidate which has already been shown to improve patients lives.
View source version on newsdirect.com: https://newsdirect.com/news/race-oncology-at-the-heart-of-cancer-care-711655111
Race Oncology Ltd
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Boston New Times journalist was involved in the writing and production of this article.